Search Results

You are looking at 1 - 10 of 12 items for :

  • corticotroph pituitary tumors x
Clear All
Open access

Solène Castellnou, Alexandre Vasiljevic, Véronique Lapras, Véronique Raverot, Eudeline Alix, Françoise Borson-Chazot, Emmanuel Jouanneau, Gérald Raverot and Hélène Lasolle

Introduction Cushing’s disease is a rare disorder defined as chronic hypercortisolism due to a corticotropin-secreting pituitary tumor (corticotroph tumor) ( 1 ). Chronic cortisol excess is responsible for multisystem morbidity, contributing

Open access

Benedetta Zampetti, Erika Grossrubatscher, Paolo Dalino Ciaramella, Edoardo Boccardi and Paola Loli

corticotrophs by the longstanding hypercortisolemia is crucial for the diagnostic accuracy of BIPSS, because it ensures that any ACTH measured is secreted by tumor tissue (pituitary or ectopic). Use of CRH As ACTH secretion is intermittent and blood

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

.5%) ( 5 ). The pituitary tumors in acromegaly are generally macroadenomas (>10 mm in diameter), and nearly half of patients have local tumor invasion at diagnosis. Many studies have examined the molecular genetic pathophysiology of acromegaly. The best

Open access

Giovanni Tulipano

growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor att20 cells . Molecular and Cellular Endocrinology 2018 53 – 61 . ( ) 98 Gao J Liu Y Han G Deng K Liu X Bao

Open access

Tao Mei, Jianhe Zhang, Liangfeng Wei, Xingfeng Qi, Yiming Ma, Xianhua Liu, Shaohua Chen, Songyuan Li, Jianwu Wu and Shousen Wang

Introduction Pituitary adenomas (PA) are among the most common intracranial tumors, accounting for 10–15% of primary intracranial tumors ( 1 ). It has been confirmed by positron emission tomography and tumor cell culture experiments that PA

Open access

Emmanuelle Motte, Anya Rothenbuhler, Stephan Gaillard, Najiba Lahlou, Cécile Teinturier, Régis Coutant and Agnès Linglart

experienced multidisciplinary team, defined by the Pituitary Society as Pituitary Tumor Centers of Excellence (PTCOE) ( 32 ). Like in adults, the ideal treatment is based on excision of the ACTH-secreting corticotroph adenoma; however, several factors may

Open access

Nidan Qiao

hormone-secreting pituitary adenomas: outcomes and analysis of remission rates and tumor biochemical activity with respect to tumor invasiveness . WNEU 2017 102 651.e1 – 658.e1 . ( ) 20 Cebula H

Open access

Milène Tetsi Nomigni, Sophie Ouzounian, Alice Benoit, Jacqueline Vadrot, Frédérique Tissier, Sylvie Renouf, Hervé Lefebvre, Sophie Christin-Maitre and Estelle Louiset

hyperandrogenism, after exclusion of other pathologies such as 21-hydroxylase (OH) deficiency, androgen-secreting tumors or Cushing's syndrome (4) . Androgen-secreting tumors are typically ovarian or adrenal tumors. They represent less than 0.2% of

Open access

J Brossaud, V Pallet and J-B Corcuff

antagonists of these pathways is not available yet. A use of retinoids in pituitary tumours especially corticotroph adenomas may be emerging. Well-tolerated, clinically available retinoids used for skin or hematologic diseases, renders clinical studies

Open access

Boni Xiang, Ran Tao, Xinhua Liu, Xiaoming Zhu, Min He, Zengyi Ma, Yehong Yang, Zhaoyun Zhang, Yiming Li, Zhenwei Yao, Yongfei Wang and Hongying Ye

(ACTH)-dependent ( 1 ), and 20% is ACTH-independent. Pituitary corticotroph adenoma (Cushing’s disease (CD)) is the most common cause ( 2 ), followed by primary unilateral adrenal adenomas and ectopic adrenocorticotropic syndrome (EAS). The clinical